留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

早期肠道菌群干预对帕金森病患者便秘症状及多巴丝肼疗效的影响

徐玲,  赵岩,  茆玲,  张习红

downloadPDF
文章导航 > 药学实践与服务  > 2018 >  36(6): 547-550
徐玲, 赵岩, 茆玲, 张习红. 早期肠道菌群干预对帕金森病患者便秘症状及多巴丝肼疗效的影响[J]. 药学实践与服务, 2018, 36(6): 547-550. doi: 10.3969/j.issn.1006-0111.2018.06.015
引用本文: 徐玲, 赵岩, 茆玲, 张习红. 早期肠道菌群干预对帕金森病患者便秘症状及多巴丝肼疗效的影响[J]. 药学实践与服务, 2018, 36(6): 547-550. doi: 10.3969/j.issn.1006-0111.2018.06.015
shu
XU Ling, ZHAO Yan, MAO Ling, ZHANG Xihong. Constipation alleviation and the efficacy improvement of levodopa and benserazide in Parkinson patients with early intestinal flora intervention[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 547-550. doi: 10.3969/j.issn.1006-0111.2018.06.015
Citation: XU Ling, ZHAO Yan, MAO Ling, ZHANG Xihong. Constipation alleviation and the efficacy improvement of levodopa and benserazide in Parkinson patients with early intestinal flora intervention[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 547-550. doi: 10.3969/j.issn.1006-0111.2018.06.015
shu

早期肠道菌群干预对帕金森病患者便秘症状及多巴丝肼疗效的影响

doi: 10.3969/j.issn.1006-0111.2018.06.015

  • 南京鼓楼医院六合分院临床药学室, 南京 211500;

  • 南京鼓楼医院六合分院神经内科, 南京 211500

Constipation alleviation and the efficacy improvement of levodopa and benserazide in Parkinson patients with early intestinal flora intervention

  • Department of Clinical Pharmacy, Liuhe Branch of Nanjing Drum Tower Hospital, Nanjing 211500, China;

  • Department of Neurology, Liuhe Branch of Nanjing Drum Tower Hospital, Nanjing 211500, China

  • 摘要: 目的 探讨早期肠道菌群干预对帕金森病（PD）患者肠道便秘症状及多巴丝肼疗效的影响，为临床治疗提供参考。 方法 纳入2015月1月至2017年10月我院神经内科初次诊断的PD患者114例，随机分为肠道菌群干预组（n=57）与对照组（n=57），两组均予多巴丝肼片常规初始治疗，干预组在此基础上加用三联活菌制剂调理肠道菌群，采用便秘患者生活质量量表（PAC-QOL）等评估患者便秘症状及满意度，采用统一帕金森病评定量表（UPDRS-Ⅲ）等评估两组患者治疗前后的运动症状及心理状态。 结果 1干预组较治疗前及较对照组的PAC-QOL，Bristol粪便性状量表（BSFS）评分改善显著，差异有统计学意义（P<0.05）；2两组患者较治疗前UPDRS-Ⅲ运动评分均有改善，差异有统计学意义（P<0.05），干预组较对照组4周时UPDRS-Ⅲ评分有下降，差异有统计学意义（P<0.05）；3干预组较对照组治疗后医院焦虑量表（HAD-A）、医院抑郁量表（HAD-D）、匹兹堡睡眠质量指数（PSQI）评分均有下降，差异有统计学意义（P<0.05）。 结论 早期肠道菌群干预能有效改善PD患者的便秘症状及焦虑睡眠等心理状态，可能有早期增强多巴丝肼制剂对运动症状的疗效，但远期影响仍有待研究。
    Abstract: Objective To investigate the effect of early intestinal flora intervention on the symptoms and the efficacy of Levodopa and Benserazide in Parkinson's disease (PD), provide a reference for clinical treatment. Methods 114 patients diagnosed as PD for the first time in our department of neurology from January 2015 to October 2017 were randomly divided into intervention group (n=57) and control group (n=57). Both groups received Levodopa and Benserazide, A triple live bacterial preparation was given to the intervention group only to regulate the intestinal flora. Patient-Assessment of Constipation Quality of Life (PAC-QOL) was used to assess the constipation symptoms and patient's satisfaction. The Unified Parkinson's Disease Rating Scale (UPDRS Ⅲ) was used to evaluate the motor symptoms and psychological status for the patients in both groups before and after treatments. Results 1 The PAC-QOL and BSFS scores in intervention group were improved significantly compared to those before treatment (P<0.05); 2 After the treatments, the UPDRS Ⅲ scores in both groups were improved significantly (P<0.05). The UPDRS Ⅲ score in the intervention group was significantly lower than that in the control group at 4 weeks (P<0.05). 3 Compared with the control group, the HAD-A, HAD-D and PSQI Score were decreased in the intervention group. (P<0.05). Conclusion Early intestinal flora intervention effectively alleviated constipation symptom and improved therapeutic effects of Levodopa and Benserazide preparation. However, the long-term effect remains to be studied.
  • [1] BRAAK H, DE VOS R A I, BOHL J, et al. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology[J]. Neurosci Lett, 2006, 396(1):67-72.
    [2] 中华医学会神经病学分会运动障碍及帕金森病学组.帕金森病的诊断[J].中华神经科杂志,2006,(6):408-409.
    [3] BERG D, POSTUMA RB, ADLER CH, et al. MDS research criteria for prodromal Parkinson's disease[J]. Mov Disord, 2015, 30(12):1600-1611.
    [4] ZHANG TM, YU SY, GUO P, et al. Nonmotor symptoms in patients with Parkinson disease:A cross-sectional observational study[J]. Medicine (Baltimore), 2016, 95(50):e5400.
    [5] ABBOTT RD, PETROVITCH H, WHITE LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease[J]. Neurology, 2001, 57(3):456-462.
    [6] PETROVITCH H, ABBOTT RD, ROSS GW, et al. Bowel movement frequency in late-life and substantia nigra neuron density at death[J]. Mov Disord, 2009, 24(3):371-376.
    [7] KESHAVARZIAN A, GREEN SJ, ENGEN PA, et al. Colonic bacterial composition in Parkinson's disease[J]. Mov Disord, 2015, 30(10):1351-1360.
    [8] FANG X. Potential role of gut microbiota and tissue barriers in Parkinson's disease and amyotrophic lateral sclerosis[J]. Int J Neurosci, 2016, 126(9):771-776.
    [9] NIELSEN HH, QIU J, FRⅡS S, et al. Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark[J]. Eur J Neurol, 2012, 19(6):864-869.
    [10] DEVOS D, LEBOUVIER T, LARDEUX B, et al. Colonic inflammation in Parkinson's disease[J]. Neurobiol Dis, 2013, 50:42-48.
    [11] FASAN A, BOVE F, GABRIELLI MA, et al. The role of small intestinal bacterial overgrowth in Parkinson's disease[J].Mov Disord,2013,28(9):1241-1249.
    [12] HOLMQVIST S, CHUTNA O, BOUSSET L, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats[J]. Acta Neuropathol, 2014, 128(6):805-820.
    [13] 王文建,郑跃杰.肠道菌群与中枢神经系统相互作用及相关疾病[J].中国微生态学杂志,2016,28(2):240-245.
    [14] ANIL ANANTHASWAMY.Faecal transplant eases symptoms of Parkinson's disease[J].New Scientist,209:8-9.
    [15] BARICHELLA M, PACCHETTI C, BOLLIRI C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease:an RCT[J]. Neurology, 2016, 87(12):1274-1280.
  • [1] 郭灵怡, 刘艳超, 高路, 刘瑞瑶, 吕权真, 俞媛.  醋酸卡泊芬净单硬脂酸甘油酯纳米粒抗白色念珠菌感染的增效作用研究 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202310043
    [2] 戴菲菲, 傅翔, 陈琼年, 俞苏纯.  上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
    [3] 黄韵, 张正银, 金英, 郑怡菁, 李铁军, 孙莉莉.  耐碳青霉烯类肺炎克雷伯菌及大肠埃希菌临床分离株耐药性及耐药基因分析 . 药学实践与服务, 2024, 42(10): 439-444. doi: 10.12206/j.issn.2097-2024.202309059
    [4] 史生辉, 石飞, 雷琼, 王亚峰, 吴雪花.  青藏高原肺结核合并念珠菌感染患者的病原菌分布特点及耐药率分析 . 药学实践与服务, 2024, 42(6): 260-262, 272. doi: 10.12206/j.issn.2097-2024.202304014
    [5] 石晓萍, 吕迁洲, 李晓宇, 许青.  泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202401050
    [6] 陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾.  基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
    [7] 尹小娟, 台力丽, 肖俊峰, 季波.  铜绿假单胞菌合并按蚊伊丽莎白菌肺部感染的病例分析 . 药学实践与服务, 2024, 42(5): 223-226. doi: 10.12206/j.issn.2097-2024.202310042
    [8] 瞿文君, 白若楠, 崔力, 周琰.  基于联合库存的公立医院多院区药品采购模式分析 . 药学实践与服务, 2024, 42(7): 315-318. doi: 10.12206/j.issn.2097-2024.202401002
    [9] 姚小静, 计佩影, 陆峰, 施国荣, 傅翔.  表面增强拉曼光谱法快速测定尿液中曲马多的研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202401072
    [10] 徐飞, 陈瑾, 鲁育含, 李志勇.  肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3483
  • HTML全文浏览量:  878
  • PDF下载量:  274
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-05-08
  • 修回日期:  2018-09-19

早期肠道菌群干预对帕金森病患者便秘症状及多巴丝肼疗效的影响

doi: 10.3969/j.issn.1006-0111.2018.06.015
  • 南京鼓楼医院六合分院临床药学室, 南京 211500;
  • 南京鼓楼医院六合分院神经内科, 南京 211500
  • 收稿日期: 2018-05-08
  • 修回日期: 2018-09-19

摘要: 目的 探讨早期肠道菌群干预对帕金森病（PD）患者肠道便秘症状及多巴丝肼疗效的影响，为临床治疗提供参考。 方法 纳入2015月1月至2017年10月我院神经内科初次诊断的PD患者114例，随机分为肠道菌群干预组（n=57）与对照组（n=57），两组均予多巴丝肼片常规初始治疗，干预组在此基础上加用三联活菌制剂调理肠道菌群，采用便秘患者生活质量量表（PAC-QOL）等评估患者便秘症状及满意度，采用统一帕金森病评定量表（UPDRS-Ⅲ）等评估两组患者治疗前后的运动症状及心理状态。 结果 1干预组较治疗前及较对照组的PAC-QOL，Bristol粪便性状量表（BSFS）评分改善显著，差异有统计学意义（P<0.05）；2两组患者较治疗前UPDRS-Ⅲ运动评分均有改善，差异有统计学意义（P<0.05），干预组较对照组4周时UPDRS-Ⅲ评分有下降，差异有统计学意义（P<0.05）；3干预组较对照组治疗后医院焦虑量表（HAD-A）、医院抑郁量表（HAD-D）、匹兹堡睡眠质量指数（PSQI）评分均有下降，差异有统计学意义（P<0.05）。 结论 早期肠道菌群干预能有效改善PD患者的便秘症状及焦虑睡眠等心理状态，可能有早期增强多巴丝肼制剂对运动症状的疗效，但远期影响仍有待研究。

English Abstract

徐玲, 赵岩, 茆玲, 张习红. 早期肠道菌群干预对帕金森病患者便秘症状及多巴丝肼疗效的影响[J]. 药学实践与服务, 2018, 36(6): 547-550. doi: 10.3969/j.issn.1006-0111.2018.06.015
引用本文: 徐玲, 赵岩, 茆玲, 张习红. 早期肠道菌群干预对帕金森病患者便秘症状及多巴丝肼疗效的影响[J]. 药学实践与服务, 2018, 36(6): 547-550. doi: 10.3969/j.issn.1006-0111.2018.06.015
shu
XU Ling, ZHAO Yan, MAO Ling, ZHANG Xihong. Constipation alleviation and the efficacy improvement of levodopa and benserazide in Parkinson patients with early intestinal flora intervention[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 547-550. doi: 10.3969/j.issn.1006-0111.2018.06.015
Citation: XU Ling, ZHAO Yan, MAO Ling, ZHANG Xihong. Constipation alleviation and the efficacy improvement of levodopa and benserazide in Parkinson patients with early intestinal flora intervention[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 547-550. doi: 10.3969/j.issn.1006-0111.2018.06.015
shu

    全文HTML

参考文献 (15)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计